Patents Assigned to BTG International Limited
-
Publication number: 20120071548Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.Type: ApplicationFiled: September 21, 2011Publication date: March 22, 2012Applicant: BTG International LimitedInventor: Richard L. Veech
-
Publication number: 20120053340Abstract: A salt of a compound of formula (I) may be made with methanesulfonic acid. The salt and salts with other acids may be prepared by recovering from methyl tert-butyl ether (MTBE).Type: ApplicationFiled: November 2, 2011Publication date: March 1, 2012Applicant: BTG International LimitedInventor: Neil John Hunt
-
Patent number: 8122917Abstract: A foam transfer device is described, for use with aerosol canister apparatus for producing a sclerosant foam for the treatment of, inter alia, varicose veins. The device enables diversion of an initial quantity of below-specification foam from the canister to waste, e.g. to an integral waste chamber, before dispensing a further quantity of foam for use in treatment. The switching of the flow from the waste chamber to a different outlet for use is accomplished without interrupting the flow from the aerosol canister since this would cause the foam to drop below specification again. The waste chamber may be transparent so that the foam entering it can be observed and a decision made by a user when to stop diverting foam to waste. Alternatively, the foam may be diverted automatically e.g. when a set time has elapsed or a set volume of foam dispensed. The foam for use is normally dispensed into a syringe for subsequent injection into a varicose vein of a patient.Type: GrantFiled: September 9, 2010Date of Patent: February 28, 2012Assignee: BTG International LimitedInventors: Anthony David Harman, David Dakin Iowerth Wright, Jam Wilem Marinus Mijers, Stuart Brian William Kay, Christopher John Hurlstone, Julina Richard Dixon, Andrew Gordon Pocock, Brendan Hogan
-
Patent number: 8114903Abstract: A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group —(CH2)n—CR4R5—(CH2)m— wherein n and m are independently selected integers 0, 1 or 2 and R4 and R5 are independently selected from H, C1-18 alkyl, C1-18alkoxy, C1-18n hydroxyalkyl, C2-18 alkenyl and C6-18aryl or aralykyl and R3 is the a fatty acyl group of an essential polyunsaturated fatty acid.Type: GrantFiled: July 2, 2010Date of Patent: February 14, 2012Assignee: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Paul Barraclough, Anthony P Dolan
-
Publication number: 20120035736Abstract: A tibial knee joint prosthesis for attachment to a suitably prepared tibial bone, providing bearing portions in the lateral and medial compartments. The lateral and medial bearing surfaces of the component are inclined at different angles in the anterior to posterior direction of the knee, so that when mounted to the tibia, the lateral bearing surface of the prosthesis is higher than the medial bearing surface to the posterior side of the knee. In this way the lateral ligament is tightened progressively more than the medial ligament as the knee moves from extension to flexion, resulting in increased stability in the lateral compartment.Type: ApplicationFiled: May 11, 2011Publication date: February 9, 2012Applicant: BTG International LimitedInventors: John J. O'Connor, John W. Goodfellow, David Murray
-
Patent number: 8101653Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.Type: GrantFiled: January 26, 2004Date of Patent: January 24, 2012Assignee: BTG International LimitedInventor: Richard L. Veech
-
Publication number: 20120015947Abstract: A compound of formula (I): in which— X represents O or CH2; R3 and R4 each independently represent hydrogen or C1-6 alkyl; p represent 0 or 1; and R represents a five- or six-membered saturated or unsaturated ring selected from: or R represents a five- or six-membered oxo-substituted unsaturated ring selected from: wherein R1 and R2 together represent an oxo group, or R1 and R2 each represent hydrogen, methoxy or ethoxy, or R1 and R2 together with the interjacent carbon atom represent a 1,3-dioxolane or 1,3-dioxane ring, attached via the 2 position and optionally bearing one or more methyl or ethyl groups; or a salt thereof, is suitable for the treatment of anxiety and depression.Type: ApplicationFiled: August 5, 2011Publication date: January 19, 2012Applicant: BTG International LimitedInventors: Phillip Parsons, Silvia Trasciatti, Sergio Rosini, Michael Annis
-
Patent number: 8091801Abstract: Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.Type: GrantFiled: June 18, 2009Date of Patent: January 10, 2012Assignee: BTG International LimitedInventors: Tariq Osman, Sheila Bronwen Shilton-Brown, David Dakin Iorwerth Wright, Anthony David Harman, Timothy David Boorman
-
Patent number: 8076474Abstract: A salt of a compound of formula (I) may be made with methanesulfonic acid. The salt and salts with other acids may be prepared by recovering from methyl tert-butyl ether (MTBE).Type: GrantFiled: February 4, 2010Date of Patent: December 13, 2011Assignee: BTG International LimitedInventor: Neil John Hunt
-
Patent number: 8066776Abstract: Prosthesis for implantation in the knee having a tibial component for attachment to the tibia. The tibial component has a first, upper surface and a second, lower surface opposite the first surface for attachment to the tibia. The first surface includes a lateral bearing region having a convex form and a medial bearing region having a flat form, arranged such that the respective angles of inclination in sagittal planes of the lateral and medial bearing regions of the component in situ when fitted to the tibia are different.Type: GrantFiled: August 11, 2009Date of Patent: November 29, 2011Assignee: BTG International LimitedInventors: John J. O'Connor, John W. Goodfellow, David Murray
-
Publication number: 20110288288Abstract: A compound of formula (I) or a pharmaceutically-acceptable salt thereof, may be made by a process including a triflating step by which a ketone of formula (II) is converted into a triflate of formula (III) in the presence of a base comprising a tertiary or heterocyclic amine such that the pKa of the conjugate acid at 25° C. is within the range 5.21 to 12.Type: ApplicationFiled: July 27, 2011Publication date: November 24, 2011Applicant: BTG International LimitedInventor: Paul S. Bury
-
Patent number: 8063056Abstract: Cyclopenta[g]quinazolines of the formula (I):— wherein: A is a group OR or NR0R1 wherein R0 and R1 are each independently hydrogen C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl, C2-4 halogenoalkyl or C1-4 cyanoalkyl, or R0 and R1 together with the intermediate N form a five- or six-membered heterocyclic ring; p is an integer in the range 1 to 4; R2 is hydrogen, C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl, C2-4 halogenoalkyl or C1-4 cyanoalkyl; Ar1 is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C1-4 alkyl and C1-4 alkoxy; and R3 is a group of one of the following formulae: -A1-Ar2-A2-Y1-A5-CON(R)CH(Y4)Y5-A8-X—Ar4 and pharmaceutically acceptable salts or esters thereof are of therapeutic value particularly in the treatment of cancer.Type: GrantFiled: March 3, 2010Date of Patent: November 22, 2011Assignee: BTG International LimitedInventors: Vasilios Bavetsias, Ann L Jackman
-
Patent number: 8053432Abstract: A compound of formula (I): in which X represents O or CH2; R3 and R4 each independently represent hydrogen or C1-6 alkyl; p represent 0 or 1; and R represents a five- or six-membered saturated or unsaturated ring selected from: formula (II), (III) and (IV); or R represents a five- or six-membered oxo-substituted unsaturated ring selected from: (V) and (VI); wherein R1 and R2 together represent an oxo group, or R1 and R2 each represent hydrogen, methoxy or ethoxy, or R1 and R2 together with the interjacent carbon atom represent a 1,3-dioxolane or 1,3-dioxane ring, attached via the 2 position and optionally bearing one or more methyl or ethyl groups; or a salt thereof, is suitable for the treatment of anxiety and depression.Type: GrantFiled: June 15, 2010Date of Patent: November 8, 2011Assignee: BTG International LimitedInventors: Phillip Parsons, Silvia Trasciatti, Sergio Rosini, Michael Annis
-
Patent number: 7998943Abstract: A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of the formula I to a patient in need thereof wherein R1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1; R2 is H, —OH, C1-6 alkoxy or Sac 2; R3 is H, —OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties, and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof.Type: GrantFiled: July 6, 2006Date of Patent: August 16, 2011Assignee: BTG International LimitedInventors: Rakesh Chibber, Russell Hagan
-
Patent number: 7993641Abstract: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.Type: GrantFiled: October 16, 2006Date of Patent: August 9, 2011Assignee: BTG International LimitedInventors: Herman Waldmann, Mark Frewin
-
Patent number: 7994289Abstract: An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.Type: GrantFiled: June 18, 2003Date of Patent: August 9, 2011Assignee: BTG International LimitedInventors: Herman Waldmann, Mark Frewin
-
Publication number: 20110184063Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both ?-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of ?-linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of ?-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-?1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF-?1/TNF-? ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35% of the sn-2 position fatty acid residues as ?-linolenic acid.Type: ApplicationFiled: April 6, 2011Publication date: July 28, 2011Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief
-
Publication number: 20110152209Abstract: The present invention relates to the use of known and novel compounds as inhibitors of UDP-GlcNAc:Gal?1,3GalNAc-R (GlcNAc to GalNAc) ?1,6-N-acetylglucosaminyl transferase (core 2 ?1,6 N-acetylaminotransferase, core 2 GlcNAc-T-EC 2.4.1.102). Such inhibitors have applications in therapy for diseases associated with raised activity of core 2 GlcNAc-T, in particular inflammatory diseases, atherosclerosis, diabetic cardiomyopathy, cancers—including treatment or prevention of metastasis—or diabetic retinopathy.Type: ApplicationFiled: February 24, 2011Publication date: June 23, 2011Applicant: BTG International LimitedInventor: Rakesh Chibber
-
Patent number: 7964641Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterized in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: GrantFiled: August 13, 2004Date of Patent: June 21, 2011Assignee: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Patent number: 7947736Abstract: Method for the synthesis of a compound of formula H(OCH[CH3]CH2C[O])3—O-A-O—R wherein A is the residue of 1,3-butandiol and R is H or H(OCH[CH3]CH2C[O]3—. The method comprises reacting a cyclic oligomer of (R)-3-hydroxybutyrate consisting of (R)-3-hydroxybutyrate moieties with a 1,3-butandiol in an organic solvent in the presence of Candida antarctica lipase type B in a furan or pyran solvent.Type: GrantFiled: July 15, 2005Date of Patent: May 24, 2011Assignee: BTG International LimitedInventor: Richard A. Gross